Targeting <i>BRAF</i>-Mutant Colorectal Cancer: Progress in Combination Strategies.

View/ Open
Date
2017-06Author
Sundar, R
Hong, DS
Kopetz, S
Yap, TA
Type
Journal Article
Metadata
Show full item recordAbstract
BRAF mutations in colorectal cancer portend a poor prognosis, with first-line treatment often involving triplet or quadruplet chemotherapy, and single-agent targeted therapy with BRAF inhibitors failing to demonstrate clinical activity. Blockade of multiple critical nodes along the MAPK and other pathways may be necessary to improve response rates and survival. Cancer Discov; 7(6); 558-60. © 2017 AACR. See related article by van Geel et al., p. 610 .
Collections
Subject
Animals
Humans
Colorectal Neoplasms
Proto-Oncogene Proteins B-raf
Mitogen-Activated Protein Kinases
Antineoplastic Combined Chemotherapy Protocols
Mutation
Molecular Targeted Therapy
Research team
Medicine Drug Development Unit (de Bono)
Language
eng
License start date
2017-06
Citation
Cancer discovery, 2017, 7 (6), pp. 558 - 560